The Allosteric Antagonist of the Sigma-2 Receptors—Elayta (CT1812) as a Therapeutic Candidate for Mild to Moderate Alzheimer’s Disease: A Scoping Systematic Review

Nearly 35 million people worldwide live with Alzheimer’s disease (AD). The prevalence of the disease is expected to rise two-fold by 2050. With only symptomatic treatment options available, it is essential to understand the developments and existing evidence that aims to target brain pathology and d...

Descripción completa

Detalles Bibliográficos
Autores principales: Rasheed, Anum, Zaheer, Ahmad Bin, Munawwar, Aqsa, Sarfraz, Zouina, Sarfraz, Azza, Robles-Velasco, Karla, Cherrez-Ojeda, Ivan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866790/
https://www.ncbi.nlm.nih.gov/pubmed/36675950
http://dx.doi.org/10.3390/life13010001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866790/
https://www.ncbi.nlm.nih.gov/pubmed/36675950
http://dx.doi.org/10.3390/life13010001

Ejemplares similares